Early-onset pancreatic cancer: Clinical characteristics and survival outcomes

• DOI: 10.1016/j.pan.2022.04.003
• Publication Date: 2022-04-07T06:16:44Z
• Authors: Tsuyoshi Takeda; Takashi Sasaki; Yosuke Inoue; Takeshi Okamoto; Chinatsu Mori; Takafumi Mie; Takaaki Furukawa; Yuto Yamada; Akiyoshi Kasuga; Masato Matsuyama; Masato Ozaka; Yu Takahashi; Akio Saiura; Naoki Sasahira
• Keywords: Cohort Studies; Pancreatic Neoplasms; 03 medical and health sciences; 0302 clinical medicine; Antineoplastic Combined Chemotherapy Protocols; Smoking; Humans; Neoadjuvant Therapy; Retrospective Studies; 3. Good health

Early-onset pancreatic cancer (≤50 years, EOPC) is uncommon. This study aims to characterize the clinical and survival characteristics of EOPC in comparison to late-onset pancreatic cancer (>50 years, LOPC).We retrospectively investigated consecutive PC patients treated at our institution between 2010 and 2019. We analyzed and compared clinicopathological characteristics, treatments, and outcomes of EOPC and LOPC.Of 1646 PC patients identified (768 resectable/borderline resectable; 248 locally advanced; 630 metastatic), 127 (8%) had EOPC. Current smoking and heavy drinking were associated with EOPC. EOPC presented at a more advanced stage and had higher neutrophil-to-lymphocyte ratios than LOPC. Survival outcomes were similar between the two groups, both in the entire cohort and in each resectability group. In patients undergoing resection, EOPC tended to have a higher N stage (p = 0.099) and had a higher pathological stage (stage IV, 20% vs. 7%, p = 0.005) and a lower rate of macroscopically curative resection (80% vs. 93%, p = 0.006). Liver recurrence was more commonly observed in EOPC (42% vs. 23%, p = 0.015). In the metastatic cohort, combination chemotherapy regimens were more frequently administered in EOPC as first-line treatment (79% vs. 64%, p = 0.028). Both median PFS (4.4 vs. 5.3 months, p = 0.647) and OS (11.5 vs. 9.5 months, p = 0.183) were not significantly different between the two groups.EOPC presented with a more aggressive tumor biology. Survival outcomes were similar to LOPC due to more intensive treatment.